GO
Loading...

Enter multiple symbols separated by commas

Search results for "ESRX"

REFINE RESULTS

SEARCH RESULTS

About 20 results. Sort By: Date | Relevance
Linking cancer drug prices to their performance  

Should the cost of cancer drugs be tied to how well they work?
Source: CNBC.com
Cramer: The reversal of the reversal  

Mad Money host Jim Cramer says to use selloffs to get the prices you want for the stocks you need.
Source: CNBC.com
Paying for a shakeup in cancer drugs  

A major drug prescription benefits manager is pushing to change the skyrocketing pricing structure, reports CNBC's Meg Tirrell
Source: CNBC.com
Linking cancer drug prices to their performance

Express Scripts is looking at the possibility of paying more for drugs that have been proven to show more benefit, and less where the drug hasn't.
Source: CNBC.com | By: Meg Tirrell
Two parts of Express Scripts' new plan  

A new plan for Express Scripts regarding cancer drugs, with CNBC's Meg Tirrell.
Source: CNBC.com
4 Stocks, 4 trades: Airlines, Express Scripts & more  

The FMHR traders take their positions on four stocks making news today, including the airline stocks flying higher, and Express Scripts.
Source: CNBC.com
Cramer: Problem with correction calls  

CNBC's Jim Cramer explains what the main problem with market correction calls is.
Source: CNBC.com
Early movers: TIF, KORS, TOL, BWS, HRL & more

These are the stocks posting the largest moves before the bell.
Source: CNBC.com | By: Peter Schacknow
INSIGHT-Fight over hot new cholesterol drugs may be won in milligrams

Assuming approval from the U.S. Food and Drug Administration, Amgen Inc. will offer its drug, Repatha, as a biweekly 140 mg injection or a monthly injection of 420 mg, while Praluent, from Regeneron Pharmaceuticals Inc and Sanofi, will be offered in biweekly injections of 75 mg or 150 mg. Regeneron and Sanofi could enjoy a significant pricing advantage with their...
Source: Reuters | By: Deena Beasley
CORRECTED-UPDATE 2-CVS to buy pharmacy services provider Omnicare for $10.1 bln

*Deal values Omnicare at $12.7 bln, including $2.3 bln debt. May 21- CVS Health Corp, the second-largest U.S. drugstore operator, said on Thursday it will buy pharmacy services provider Omnicare Inc for $10.1 billion to expand in the growing market serving the senior patient population. CVS offered $98 per Omnicare share, representing a premium of 4 percent to...
Source: Reuters